“Strong Buy” 12-month Price Target of $15 - $18 indicates a potential price gain of 224% to 269%*
22-page research report by Harbinger Research details Investment Opportunity, Valuation Comparables... includes Profit and Loss Models thru FY2022. Brian Connell, CFA
Company Overview: Adamis is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
*Based on market close, March 19, 2014